A suite of FRs has also been reported as present in materials and products taken recently from the Swiss retail market (Zennegg, 2011). In addition, other types of compounds are also used as FRs in a variety of applications, notably PFRs. Regarding the present use of CFRs, less has been

published to date, even though some new chemicals have now been identified as CFRs. These are mainly related to the family of “Dechloranes” (Sverko et al., 2011) as further discussed below. As the number of compounds in use as FRs, and for which environmental data are being reported increases, there is a pressing need to harmonize abbreviations by which these compounds can be described in the literature (for example, using TBBPA and PBDEs as described above, and BDE47 for

2,2′,4,4′-tetrabromodiphenyl ether), with the aim of preventing future confusion. EGFR inhibitor review Unfortunately, a rather large number of abbreviations, for the less known FRs, are currently being used without any coordination. Following a request made at the BFR Symposium 2010 in Kyoto, we have now prepared a document which aims to promote improved harmonization, based on a set of criteria, of unique and practical abbreviations to be used for all BFRs, CFRs and PFRs identified to date. In this paper, we provide information relating to halogenated FRs and PFRs, including common, trade and systematic names, CAS numbers, physicochemical properties where known, together with recommended structured abbreviations (STABs) and practical abbreviations (PRABs). Also some general comments see more and suggestions are given with the aim of simplifying the abbreviation of the full chemical names of BFRs, CFRs and PFRs. All compounds listed were retrieved by reviewing the scientific literature for BFRs, CFRs and PFRs. Documents of particular use for identifying BFRs and CFRs were: WHO/IPCS, 1994 and WHO/IPCS, 1995, WHO/IPCS (1997), Örn and Bergman (2004),

Andersson et al. (2006); Harju et al. (2009), Letcher et al. (2009), Covaci et al. (2011), de Wit et al. (2011), Sverko et al. (2011); and for PFRs: van der Veen and de Boer (2012). The Liothyronine Sodium compounds are presented in three separate groups (BFRs, CFRs and PFRs) and then listed in molecular mass order within each subgroup. The sub-grouping is given below. We have chosen to list FRs holding, for example, both a phosphorus group and a halogen substituent, in each of the groups to which they belong, i.e. a BFR with a chlorine substituent is also listed in the table containing CFRs (Table 3); a PFR containing bromine substituents is also listed as a BFR. This means that some of the chemicals are listed twice. One further goal of the systematic work presented herein is to enable us to treat functional groups in chemicals in a similar way, which could also be applied for hitherto unknown BFRs, CFRs, and PFRs that may be identified as commercial products in the future.